MitoQ

Michael Greve commits €300m for rejuvenation start-ups

Latest articles

A better model organism for testing antiaging drugs?

Harvard researcher proposes the Daphnia water flea as an alternative to worms for building a scalable platform for antiaging drugs research. In many ponds and...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

What the aging field needs

Changing the narrative – Celine Halioua reveals why the aging field needs to be taught some new tricks. Celine Halioua is the Founder and CEO...

Insilico Medicine gets $255m boost for AI-powered R&D

Insilico closes $255 million to progress into human clinical trials and develop novel targets and also announces Teva Pharm collaboration. Insilico Medicine, a company driving...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
fundraising

Editor's picks

A better model organism for testing antiaging drugs?

Harvard researcher proposes the Daphnia water flea as an alternative to worms for building a scalable platform for antiaging drugs research. In many ponds and...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

What the aging field needs

Changing the narrative – Celine Halioua reveals why the aging field needs to be taught some new tricks. Celine Halioua is the Founder and CEO...
MitoQ

Click the globe for translations.

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve.

Michael Greve, founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures, announced today that he will make available an additional €300 million to be invested in rejuvenation biotech.

Longevity.Technology: €300m ($360m) is a sizeable amount to plough into rejuvenation biotech. The funds, which will be deployed via Kizoo, will be used to create and support more start-ups in the rejuvenation space, allowing Kizoo to maintain a strong commitment to its key start-ups during follow-up rounds. Crucially, it will allow therapies to advance from clinical development to public availability.

We were delighted to talk to Michael Greve ahead of today’s announcement to find out more…

With this €300 million commitment, Greve and Kizoo double down on their mission to accelerate the advent of rejuvenation biotechnology by doing lighthouse investments in entirely new, repair-based approaches that treat the root causes of aging and thus overcome age-related diseases. Through the creation of successful companies, they seek to inspire scientists, investors, and the general public by demonstrating that human rejuvenation is not science fiction anymore and that the resulting therapies are affordable and uncomplicated.

Technologies pioneered by Kizoo’s start-ups include removal of arterial plaque, decalcification of aged tissue, breaking of protein-glucose cross-links, and delivery of new mitochondria to aged cells – all aiming to prevent and repair common age-related conditions such as myocardial infarction, stroke, high blood pressure, tissue stiffening, skin aging and loss of muscle function.

Michael Greve says: “I am really grateful that we can use the funds we have created with our highly successful technology ventures to contribute to the quest to get aging under full medical control and to make age-related diseases a thing of the past. For me, it is a worthy cause that is exciting in a technological, commercial, and above all, a humanitarian way.”

Greve expects that the new funds, in combination with the strong, multi-round commitment of Kizoo to its key start-ups, should trigger co-investments of up to 3-4 times the initial amount, resulting in a significant acceleration of the development and public availability of the therapies.

Image courtesy of Michael Greve

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
MitoQ

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
fundraising

Related articles

Insilico Medicine gets $255m boost for AI-powered R&D

Insilico closes $255 million to progress into human clinical trials and develop novel targets and also announces Teva Pharm collaboration. Insilico Medicine, a company driving...

Longevity focused crypto platform to launch token auction

Lead researcher behind VitaDAO’s first project reveals more about his work and why crypto provides an exciting new funding option for longevity scientists. Later this...

Calling all longevity start-ups and scale-ups

Some news from us! Longevity.Technology's brand-new investment portal brings innovators and investors together. As a part of our mission to support the companies that will...

Oisín seed raise advances therapies for diseases of aging

Oisín Biotechnologies funding tops $9.5 million, with additional funding set to support preclinical development of its platform and investigational therapy for kidney and other age-related diseases. Seattle-based...

Dorian and HitGen to collaborate on senotherapy

Send in the senoblockers – Dorian and HitGen announce a research collaboration focused on DNA-encoded library-based drug discovery for age-related diseases. HitGen, Inc today announced...
Supps report ad middle